With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.564483-19-8,Di-tert-butyl(2′,4′,6′-triisopropyl-[1,1′-biphenyl]-2-yl)phosphine,as a common compound, the synthetic route is as follows.
(2) A suspension of the compound obtained in (1) (89.27 g), ethyl 1H-pyrazole-4-carboxylate (45.16 g), tripotassium phosphate (93.3 g), 2-di-t-butylphosphino-2′,4′,6′-triisopropyl biphenyl (9.33 g) and tris(dibenzylideneacetone)dipalladium(0) (6.7 g) in t-butyl alcohol (900 mL) was stirred for 2 hours at 90 C. under nitrogen atmosphere. The reaction mixture was concentrated under reduced pressure, and the residue was added with chloroform and water. The organic layer was separated, and the aqueous layer was extracted with chloroform. The NH-silica gel (100 mL) and sodium sulfate (100 g) were added to the organic layer, and insoluble materials were removed by filtration. The filtrate was concentrated under reduced pressure, and the residue was added with methanol. The resulting crystals were collected by filtration to yield ethyl 1-[7-methoxy-1-(4-methoxybenzyl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-1H-pyrazole-4-carboxylate (78.94 g, 66% yield) as colorless crystals. MS (APCI) m/z: 409 [M+H]+.
As the paragraph descriping shows that 564483-19-8 is playing an increasingly important role.
Reference£º
Patent; MITSUBISHI TANABE PHARMA CORPORATION; Nakajima, Tatsuo; Goi, Takashi; Kawata, Atsushi; Sugahara, Masakatsu; Yamakoshi, Shuhei; US2015/239889; (2015); A1;,
Phosphine ligand
Chiral phosphine ligands in asymmetric synthesis. Molecular structure and absolute configuration of (1,5-cyclooctadiene)-(2S,3S)-2,3-bis(diphenylphosphino)butanerhodium(I) perchlorate tetrahydrofuran solvate